Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04148105 · ClinicalTrials.gov registry record · Phase 4
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT04148105 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 19 participants.
The verdict
NCT04148105, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The investigators seek to demonstrate that the combined use of cilostazol and nimodipine will significantly decrease the rate of delayed cerebral infarction and cerebral vasospasm after cerebrovascular intervention when compared to nimodipine alone.
Interventions
- OTHER Placebo
- DRUG Cilostazol 100 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04148105
The ClinicalTrials.gov registry entry for NCT04148105 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04148105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04148105 about?
NCT04148105 is a clinical study titled "Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)". The investigators seek to demonstrate that the combined use of cilostazol and nimodipine will significantly decrease the rate of delayed cerebral infarction and cerebral vasospasm after cerebrovascular intervention when compared to nimodipine alone.
What is the current status of trial NCT04148105?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2019-11-01. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04148105?
The interventions under investigation include: Placebo (OTHER), Cilostazol 100 MG (DRUG).
Who is sponsoring clinical trial NCT04148105?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.